Tinidazole in the treatment of bacterial vaginosis
- PMID: 21072275
- PMCID: PMC2971702
- DOI: 10.2147/ijwh.s4455
Tinidazole in the treatment of bacterial vaginosis
Abstract
Bacterial vaginosis (BV) is the commonest cause of vaginal discharge in women of childbearing age. Oral metronidazole has long been established as an effective therapy in the treatment of BV. However, adverse effects due to metronidazole are frequent and this may lead to problems with adherence to a 7-day course of treatment and subsequently result in treatment failure. Oral tinidazole has been used to treat bacterial vaginosis for over 25 years but in a number of different dosage regimens. Placebo controlled trials have consistently shown increases in cure rate with tinidazole. Longer courses of treatment (eg, 1 g daily for 5 days) appear to be more effective than a 2 g oral single dose. Comparative studies suggest that oral tinidazole is equivalent to oral metronidazole, intravaginal clindamycin cream, and intravaginal metronidazole tablets, in efficacy in treating BV. However, tinidazole has a more favorable side effect profile than oral metronidazole notably with better gastrointestinal tolerability and less metallic taste. Bacterial vaginosis is associated with high rates of recurrence and appropriate management of such recurrences can prove difficult. Recurrent BV has been linked with persistence of Gardnerella vaginalis after treatment; however the clinical implications of the possible greater activity of tinidazole against G. vaginalis are not yet clear. Repeated courses of oral metronidazole may be poorly tolerated and an alternative but equally effective treatment that is better tolerated may be preferable. In comparison to oral metronidazole, cost is clearly an issue as oral metronidazole is considerably cheaper and available in generic form. However where avoidance of oral metronidazole is necessary because of side effects, oral tinidazole is a cost-effective alternative.
Keywords: Gardnerella vaginalis; bacterial vaginosis; metronidazole; tinidazole.
Similar articles
-
Susceptibility of bacterial vaginosis (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin.Anaerobe. 2017 Oct;47:115-119. doi: 10.1016/j.anaerobe.2017.05.005. Epub 2017 May 15. Anaerobe. 2017. PMID: 28522362 Free PMC article.
-
Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream.J Fam Pract. 1995 Nov;41(5):443-9. J Fam Pract. 1995. PMID: 7595261 Clinical Trial.
-
Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: the VITA RCT.Health Technol Assess. 2022 Jan;26(2):1-170. doi: 10.3310/ZZKH4176. Health Technol Assess. 2022. PMID: 35057905 Clinical Trial.
-
Characterization and Treatment of Recurrent Bacterial Vaginosis.J Womens Health (Larchmt). 2019 Sep;28(9):1218-1226. doi: 10.1089/jwh.2018.7383. Epub 2019 Aug 12. J Womens Health (Larchmt). 2019. PMID: 31403349 Review.
-
New approaches for the treatment of bacterial vaginosis.Am J Obstet Gynecol. 1993 Aug;169(2 Pt 2):479-82. doi: 10.1016/0002-9378(93)90346-k. Am J Obstet Gynecol. 1993. PMID: 8357050 Review.
Cited by
-
Women presenting to emergency departments with vaginitis should be offered single-dose empirical treatment.Acad Emerg Med. 2025 Aug;32(8):941-946. doi: 10.1111/acem.70026. Epub 2025 Mar 26. Acad Emerg Med. 2025. PMID: 40136030 Free PMC article. No abstract available.
-
Star-Shaped Poly(furfuryl glycidyl ether)-Block-Poly(glyceryl glycerol ether) as an Efficient Agent for the Enhancement of Nifuratel Solubility and for the Formation of Injectable and Self-Healable Hydrogel Platforms for the Gynaecological Therapies.Int J Mol Sci. 2021 Aug 4;22(16):8386. doi: 10.3390/ijms22168386. Int J Mol Sci. 2021. PMID: 34445090 Free PMC article.
-
Diversity and Prevalence of Helminths and Protozoa Among Pregnant Women in Tropical Ecuador: Implications for Chemotherapy.Am J Trop Med Hyg. 2024 Nov 26;112(2):307-313. doi: 10.4269/ajtmh.24-0164. Print 2025 Feb 5. Am J Trop Med Hyg. 2024. PMID: 39591647
-
Secnidazole for treatment of bacterial vaginosis: a systematic review.BMC Womens Health. 2019 Oct 21;19(1):121. doi: 10.1186/s12905-019-0822-2. BMC Womens Health. 2019. PMID: 31638955 Free PMC article.
-
Protocol for a randomized clinical trial exploring the effect of antimicrobial agents on the penile microbiota, immunology and HIV susceptibility of Ugandan men.Trials. 2019 Jul 19;20(1):443. doi: 10.1186/s13063-019-3545-7. Trials. 2019. PMID: 31324206 Free PMC article.
References
-
- Fredricks D, Fiedler BS, Marazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Eng J Med. 2005;353:1899–1911. - PubMed
-
- Amsel R, Totten PA, Spiegal CA, et al. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74:14–22. - PubMed
LinkOut - more resources
Full Text Sources
Medical